The main prognostic factors and why minimal residual disease is becoming crucial in multiple myeloma
Highlights from the International Symposium on Acute Leukemias (ISAL) 2017 in Munich
Myeloma 2016: Panel discussion on gene modified T-cells
Edward Stadtmauer et al.
The future of multiple myeloma treatment
Tolerability of monoclonal antibodies in multiple myeloma